Syon Capital’s Myriad Genetics MYGN Stock Holding History

Syon Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-12,856	Closed	-$176K	–	635
2024 Q4	$176K	Buy	+12,856	New	+$237K	0.02%	530

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Syon Capital's MYGN Position: Q1 2025 in Review

Syon Capital sold out of Myriad Genetics (MYGN) in Q1 2025, closing a stake of 12,856 shares — an estimated $176K sold.

Syon Capital first reported a position in MYGN in Q4 2024 and held it in 1 quarter. The position peaked at $176K in Q4 2024. 228 funds tracked by Wall St. Rank hold MYGN as of Q1 2025.

Syon Capital reported no remaining Myriad Genetics position as of Q1 2025 after selling out during the quarter.
Syon Capital sold 12,856 Myriad Genetics shares in Q1 2025, an estimated $176K.
Syon Capital first reported a position in Myriad Genetics in Q4 2024 and held it in 1 quarter.
Syon Capital's Myriad Genetics position peaked at $176K in Q4 2024.
228 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2025.

Based on Syon Capital's 13F filing for Q1 2025, filed 15 May 2025.